BACKGROUND: Pelvic floor functioning is an important concern for women requiring a hysterectomy for endometrial cancer. The incidence of pelvic floor symptoms has not been reported in women who have undergone a hysterectomy for early-stage endometrial cancer. OBJECTIVE: We sought to evaluate pelvic floor function in women who have had surgical treatment for early-stage endometrial cancer as part of the multinational Laparoscopic Approach to Cancer of the Endometrium trial and to compare patients' outcomes who had total abdominal vs total laparoscopic hysterectomy. STUDY DESIGN: A multinational, phase III, randomized noninferiority trial compared disease-free survival of patients who had total abdominal hysterectomy vs total laparoscopic hysterectomy. This substudy analyzes the results from a self-administered validated questionnaire on pelvic floor symptoms (Pelvic Floor Distress Inventory) administered preoperatively, and at follow-up visits 6, 18, 30, 42, and 54 months postoperatively.
Introduction
Endometrial cancer represents a significant health issue for women across the world. An estimated 300,000 women were diagnosed with endometrial cancer in 2012 and its incidence is still rising. 1 Advanced age, and an oversupply of endogenous or exogenous estrogen are the most common and well-established risk factors for endometrial cancer. Patients often have comorbidities such as obesity, diabetes mellitus, and hypertension. [2] [3] [4] [5] Treatment of endometrial cancer is primarily surgical and open abdominal surgery should generally be avoided because of its association with increased treatment-related morbidity at comparable survival outcomes. [6] [7] [8] Urinary incontinence, pelvic organ prolapse, and bowel dysfunction are common conditions following childbirth and the incidence of symptoms increases with age, the number of vaginal deliveries, and obesity. 9, 10 These conditions significantly impact on women's quality of life, have considerable financial implications, and contribute to health care utilization, as well as personal and health care costs. 11, 12 Previous studies on urinary function in gynecological cancer patients have shown a decline in function following cancer treatment. [13] [14] [15] However, these studies analyzed pelvic floor outcomes of very diverse groups of patients who had treatment for cervical and endometrial cancer, who required simple or radical hysterectomies, and even included patients who received definitive pelvic radiotherapy. It was concluded that women with early-stage endometrial cancer undergoing either total abdominal hysterectomy (TAH) or total laparoscopic hysterectomy (TLH) had better pelvic floor functional outcomes compared to those who required more aggressive cancer treatment. [13] [14] [15] [16] Data on which these conclusions have been placed are limited, and confirmation in larger studies of early-stage endometrial cancer patients is required to advise the ever-increasing number of patients of the expectations with respect to pelvic floor function after surgery. The aim of the present study was to evaluate pelvic floor function in a large cohort of women receiving surgical treatment for early-stage endometrial cancer as part of the multinational Laparoscopic Approach to Cancer of the Endometrium (LACE) trial and to compare outcomes of patients who had TAH vs TLH.
Materials and Methods

Study design and procedures
The LACE trial was a multinational randomized, phase III clinical trial comparing TAH to TLH in women with apparent stage-I endometrial cancer. All patients also had a bilateral salpingectomy and oophorectomy. A total of 760 patients were recruited through 20 gynecological cancer centers in Australia, New Zealand, and Hong Kong. Ethics approval was obtained from each hospital's human research and ethics committee. The lead human research ethics committee was the Royal Brisbane and Women's Hospital Human Research Ethics Committee (approval no. EC00172e Sept. 20, 2004) . Written informed consent was obtained from patients prior to randomization. Quality-of-life outcomes, 17 incidence and risk factors for adverse events (AEs), 7, 18 and recurrence and survival data 6 of the LACE trial have been previously reported (clinicaltrials.gov identifier: NCT00096408; Australian New Zealand Clinical Trials Registry: CTRN12606000261516).
Eligibility and exclusion criteria were described in detail previously. 19 In brief, patients with histologically confirmed endometrial adenocarcinoma of any International Federation of Gynecology and Obstetrics (FIGO) grade without evidence of extrauterine disease by imaging (computed tomography or magnetic resonance imaging of the abdomen and pelvis, and chest radiograph or chest computed tomography) were eligible. Women with a histological cell type other than endometrioid on curettage, clinically advanced disease (stage II-IV using FIGO 2009 criteria for stage or bulky lymph nodes on imaging), or uterine size >10 weeks of gestation were ineligible.
Patient-related assessments were collected prior to surgery, at week 1, and months 1, 3, and 6, postsurgery. All patients were followed up at 12 months postsurgery and then annually for survival outcomes. Patients without events were censored at the date of data lock (March 3, 2016) or date of last contact for patients lost to follow-up. Randomization procedures were also described in detail previously. 6 The surgical procedures and their steps have been described in detail earlier. 19 For the TLH an anatomically curved silicone tube with a proximal airtight cap that prevents loss of pneumoperitoneum, enables instrument access, and facilitates the safe removal of specimens transvaginally was used (McCartney tube; O.R. Company, Melbourne, Australia). TAH was performed through a vertical midline or lower transverse incision. Histopathological findings were used to determine the need for adjuvant treatment according to local institutional clinical practice guidelines, and typically were discussed in multidisciplinary meetings. The delivery and management of radiation therapy or chemotherapy was carried out according to local institutional clinical practice guidelines. Data on dosimetry or chemotherapy dosing were recorded.
All clinical AEs encountered during the clinical study were documented. The intensity of AEs was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0. The incidence of, and risk factors for, AEs were reported previously. 7, 18 For quality assurance of the surgical intervention, a rigorous accreditation process was followed as described in detail previously. 19 Surgeons were required to be: (1) certified gynecological oncologists proficient in TAH and TLH or under the direct supervision of a certified gynecological oncologist in theater; and (2) accredited by the LACE trial committee after they provided evidence of surgical proficiency.
Outcomes
While the primary outcome of the LACE trial was disease-free survival at 4.5 years, for this substudy, the outcome of interest was pelvic floor symptoms, a prespecified secondary outcome measured using the Pelvic Floor Distress Inventory (PFDI). The PFDI was only introduced after approximately half of the patients had already been enrolled in the study and only collected for patients enrolled in the latter (n ¼ 381) part of the trial. This sample size was sufficient to provide 80% power to detect a difference between the 2 groups of at least 15 points (1 SD) in the PFDI summary score. Previous work has identified that a PFDI summary score of 13.5 reflects a minimally important change among women with mild to moderate pelvic floor symptoms. 20 The PFDI 21 is a 20-item questionnaire consisting of 3 domains: the 6-item pelvic organ prolapse distress inventory, the 8-item colorectal-anal distress inventory, and the 6-item urinary distress inventory. Item response values ranged from 0-4. Following the PFDI scoring instructions, the mean score from the items in each subscale was multiplied by 25 to provide a common range for the subscales (range 0-100); the overall PFDI score was the summation of the subscale scores (range 0-300). A higher score signifies worse pelvic floor well-being. The PFDI provides a standardized and reproducible assessment of symptom severity and pelvic floor well-being changes in women with pelvic floor ajog.org
It has been reported to have good test-retest reliability, internal consistency, and in external validation it was found to be sensitive to change. 22 Use of this psychometrically robust selfadministered questionnaire is a valid way of measuring the presence, severity, and impact of a symptom or condition on a patient's activities and well-being. The PFDI was administered preoperatively, then at follow-up visits 6, 18, 30, 42, and 54 months postoperatively.
Statistical analysis
All statistical analyses were conducted according to the intention-to-treat principle.
The number of completed questionnaires at each time point was summarized. Patients who had not completed the PFDI preoperatively were excluded from analysis. Incomplete questionnaires were excluded when analyzing the PFDI total score; when analyzing the domains separately, those domains that were completed fully were included in the analysis even if the remainder of the questionnaire was incomplete.
Patient demographic and clinical characteristics are presented as frequency (%) if categorical and mean (SD) if continuous. Pelvic floor scores (total and subdomains) were summarized as mean (SD) at each time point by randomization group. Plots were constructed to graphically visualize the mean scores (with corresponding 95% confidence interval [CI]) over time for the total score and each of the pelvic organ prolapse, colorectal-anal, and urinary distress inventory domains. In addition, a patient was considered to have pelvic floor symptoms if they answered "moderate" or "severe" for at least 1 of the PFDI questions and the proportion of patients with pelvic floor symptoms was summarized at each time point.
At each time point, differences from baseline for each outcome were calculated and these differences analyzed using the repeated measure method of generalized estimating equations (which account for correlated outcomes and can account for missing data, retaining all available observations in the models). Additionally, time-bytreatment interaction terms were fitted to estimate the change in scores from baseline to each time point and to determine whether these changes differed between the treatment groups. This approach takes into account the within-patient correlation that occurs in the scores, using an exchangeable correlation structure for the robust variance estimation. As pelvic floor well-being of patients overall was good, the analyses then specifically focused on women who reported at least 1 moderate to severe pelvic floor symptom on any of the questionnaire items. The proportion of women at each time point was summarized. Stratified analyses then reported whether women had pelvic floor issues already before surgery or developed new pelvic floor issues after surgery, and whether these resolved or remained at subsequent time points. The proportion of women with pelvic floor symptoms was also assessed depending on whether or not adjuvant therapy was received.
All analyses were conducted in SAS, Version 9.3 (SAS Institute Inc, Cary, NC) and STATA, Version 14.1 (StataCorp, College Station, TX) with significance testing at the 5% level (2-sided). No statistical adjustments to the analysis were made for multiple testing or to account for missing data.
Results
Of the 760 patients randomized into the LACE trial, 381 patients completed the PFDI questionnaire preoperatively and at least 1 follow-up PFDI questionnaire. Of these, 195 patients were in the TAH group with 186 patients in the TLH group (Figure 1) .
Baseline characteristics were similar between randomization groups (Table 1) . Demographic and clinical characteristics were representative of the overall LACE population (Supplementary Table 1) .
Preoperatively, of the 381 participating patients, 322 (85%) patients provided a complete PFDI response with all 3 subscales answered. By 54 months postoperatively, participation had dropped to 207 (54%) due to death and/or disease progression (n ¼ 41, 24%), 88 (51%) patients had not been followed up to the 54-month time point, and the remaining 45 (26%) did not complete their questionnaire at the 54-month time point. For the individual scales, the pelvic organ prolapse domain had the highest completion rate (92-97% over time) while Table 2 ). Figure 2 shows the mean scores (with 95% CI around the mean) for PFDI and domains at the prespecified time points, according to treatment group. Within both treatment groups, there was an initial improvement in pelvic floor function 6 months postsurgery primarily due to pelvic organ prolapse, and urinary distress domains. Patients in the TLH group consistently had a lower pelvic floor functioning score indicating better well-being, which was most pronounced in the urinary distress domain, but the difference between the TAH and TLH group scores was not statistically significant.
Summary of PFDI scores over time
Change in PFDI scores over time
The results from the generalized estimating equation models assessing the difference in change from baseline between the TLH and TAH groups are presented as a forest plot in Figure 3 and Supplementary Tables 3 and 4 . For all the models, the interaction between treatment and time was not statistically significant, suggesting that the change in PFDI over time did not differ between the randomization groups. At 6 months postsurgery both treatment groups experienced an improvement in total PFDI score (TAH: mean change e11.17; 95% CI, e17.11 to e5.24; TLH: mean change e10.25; 95% CI, e16.31 to e4.19). However, there was no evidence of a significant difference between the treatment groups over time in terms of change from baseline PFDI scores with CIs all overlapping the 0 (Figure 3) .
Patients in both the TAH and TLH groups showed an improvement from baseline in the pelvic organ prolapse domain at each time point; however, there was no evidence to support a difference between the 2 treatment groups Total Pelvic Floor Distress Inventory (PFDI) and domain scores over time by treatment group (mean score with 95% confidence interval) CRADI, colorectal-anal distress inventory; FU, follow up; POPDI, pelvic organ prolapse distress inventory; TAH, total abdominal hysterectomy; TLH, total laparoscopic hysterectomy; UDI, urinary distress inventory. ajog.org GYNECOLOGY Original Research in change in the pelvic organ prolapse symptoms (interaction P value ¼ .79). Similarly, both treatment groups showed an improvement at 6 months postsurgery in the urinary distress domain (TAH: mean change e4.60; 95% CI, e7.47 to e1.79; TLH: mean change e4.19; 95% CI, e7.12 to e1.26) (Figure 3 ). There were no significant changes in the colorectal-anal distress domain over time or between treatment groups.
Although the proportion of patients with at least 1 moderate to severe pelvic floor problem was higher in the TAH group overall, and in the pelvic organ prolapse and urinary distress domains across most postsurgical time points, the difference in the proportions of women in the TAH or TLH groups who reported at least 1 symptom was small (about 3-5%) ( Table 2 ). The stratified summary of patients shows that 30% in both groups had no moderate to severe symptoms at baseline and throughout the study observation period; 43% of patients in the TAH and 48% of patients in the TLH group had 1 moderate to severe symptom at baseline, and 24% of patients in the TAH group, and 19% in the TLH group developed 1 moderate to severe new symptoms after baseline. Of those women reporting either existing or new symptoms about half resolved and half persisted in both treatment Forest plot of generalized estimating equation estimates for mean difference (95% confidence interval [CI]) in pelvic floor well-being scores from baseline between total abdominal hysterectomy (TAH) and total laparoscopic hysterectomy (TLH) group CRADI, colorectal-anal distress inventory; FU, follow up; PFDI, Pelvic Floor Distress Inventory; POPDI, pelvic organ prolapse distress inventory; UDI, urinary distress inventory.
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Original Research GYNECOLOGY ajog.org groups (Table 3 ). There was no difference in persisting or new pelvic floor symptoms between women who did or did not receive adjuvant therapy (Supplementary Table 5 ).
Comment
This study provides some answers to questions commonly asked by patients who require surgery for endometrial cancer about how their symptoms of urinary incontinence, pelvic organ prolapse, and bowel dysfunction may progress. Women in both groups improved initially and their scores then slowly declined while maintaining some beneficial gains compared to their presurgical pelvic floor well-being. The data also reported here show that there was no difference between TLH and TAH with respect to pelvic floor symptoms for up to 54 months postsurgery. These findings will reassure women undergoing hysterectomy for endometrial cancer, either by TAH or TLH.
The data provided here have been obtained through a prospective, randomized trial using a validated questionnaire that was completed by patients prior to surgery and up to 54 months postsurgery at multiple time points. Recently, the results of 3 randomized controlled clinical trials were published suggesting that TLH is superior to TAH in regard to short-term outcomes and equivalent with respect to survival outcomes. 6, 8, 23 The data reported here provide additional empirical evidence by demonstrating that women who receive TLH will have similar outcomes compared to women treated by TAH with respect to pelvic floor functioning.
Our findings extend previous studies by directly comparing 2 approaches to total hysterectomy in a homogenous group of patients with early endometrial cancer. Previous studies on the pelvic floor function after hysterectomy have mainly enrolled women with benign indications, or concentrated on the differences in outcomes between total and subtotal hysterectomy. A Cochrane review comparing those 2 techniques found no difference in regards to urinary incontinence, bowel function, or sexual function. 24 However, comparing prehysterectomy and posthysterectomy scores, there was an overall improvement in symptoms of urinary incontinence posthysterectomy noted in that review for both total and subtotal hysterectomy. The only previous study assessing bowel function found no difference preoperatively or postoperatively between the different routes of hysterectomy, and no changes over time. 25 Sexual function was also not found to be different between the different hysterectomy techniques, with a trend toward improvement postoperatively. 24 Subsequently, another Cochrane review specifically examining the impact of route of hysterectomy for benign conditions noted an absence of high-quality data on urinary, bowel, sexual function, and quality of life and suggested the collection of long-term data for all of these patient-reported outcomes. 26 The importance of using data from prospective studies when examining pelvic floor function and quality of life has been acknowledged by clinicians and women alike. Previously, the perception of deterioration of pelvic floor function has been related to (21) 32 (21) 31 (22) 25 (22) 24 (24) TLH 43 (23) 21 (13) 31 (22) 21 (16) 13 (12) 12 (11) POPDI-6 (only)
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women dating the onset of their symptoms to a significant life event (eg, a hysterectomy). 27 However, this concern has been not be confirmed by prospective studies on hysterectomy for benign conditions. 24, 25 Women in the present study had, on average, good pelvic floor functioning, and the average score did not change significantly after surgery in either group. The present study now provides evidence for women who require a hysterectomy for early-stage endometrial cancer, and who have 1 moderate to severe symptom before surgery, that at least half can expect a resolution of those symptoms.
Previous studies on women who require hysterectomy for cervical or endometrial cancer have found an increase in urinary and bowel dysfunction secondary to radical hysterectomy and adjuvant pelvic radiation therapy being associated with more severe urinary and bowel symptoms, and impact on quality of life. [13] [14] [15] In contrast, most patients on the LACE trial had a Piver type 1 hysterectomy and pelvic floor function, in terms of urinary, bowel, and prolapse symptoms, and did not deteriorate. This could point to the possibility that pelvic floor symptoms experienced by women after gynecological cancer in previous studies may arise as a cause of nerve damage inflicted by radical hysterectomy with or without postoperative radiation treatment, rather than a standard Piver type 1 hysterectomy. [28] [29] [30] In conclusion, this study adds to the understanding of pelvic floor function for women following hysterectomy, particularly after an endometrial cancer diagnosis, with reassurance that their function is unlikely to deteriorate after surgery with Piver type 1 hysterectomy for endometrial cancer. Our study addresses some of previously raised research questions and provides answers for clinicians and women on what they can expect following either open or laparoscopic hysterectomy for stage I endometrial cancer. This should aid in the counseling process prior to hysterectomy via open or laparoscopic routes. n (14) 55 (14) 27 (14) 18 (10) Grade of differentiation 1 (Well differentiated) 223 (63) 259 (64) 125 (64) 115 (62) 2 (Moderately differentiated) 107 (30) 120 (29) 53 (27) 54 (29) 3 (Poorly differentiated) 23 (7) 28 (7) 17 (9) 17 (9) Surgical stage Missing 3 (1) 4 (1) 1 (1) 1 (1 (14) 20 (10) 23 (12) II 45 (13) 32 (8) 27 (14) 15 (8) IIIA 4 (1) 11 (3) 3 (2) 5 (3)
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